Ledyard National Bank raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,290 shares of the biopharmaceutical company’s stock after acquiring an additional 3,465 shares during the period. Ledyard National Bank’s holdings in Gilead Sciences were worth $1,024,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently bought and sold shares of GILD. BlackRock Inc. boosted its position in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. FMR LLC lifted its holdings in shares of Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after acquiring an additional 258,005 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after acquiring an additional 116,780 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Gilead Sciences by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock worth $1,027,436,000 after acquiring an additional 136,884 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.52 during mid-day trading on Wednesday, reaching $81.20. 4,160,860 shares of the company traded hands, compared to its average volume of 8,878,577. The firm has a market capitalization of $106,150.00, a P/E ratio of 10.56, a P/E/G ratio of -1.86 and a beta of 1.24. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s revenue was down 18.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.70 EPS. sell-side analysts expect that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio is currently 27.05%.
In related news, EVP James R. Meyers sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares in the company, valued at $8,241,851.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 430,268 shares of company stock worth $34,074,395 in the last quarter. 1.30% of the stock is owned by corporate insiders.
Several equities research analysts recently weighed in on the stock. Barclays reaffirmed an “overweight” rating and set a $95.00 target price (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Mizuho set a $95.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, February 5th. Finally, Leerink Swann reiterated a “market perform” rating and set a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $88.61.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Stake Boosted by Ledyard National Bank” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/ledyard-national-bank-boosts-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.